Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurosense Therapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NRSN
Nasdaq
8731
https://www.neurosense-tx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurosense Therapeutics Ltd
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
- Apr 22nd, 2024 12:30 pm
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
- Apr 18th, 2024 12:30 pm
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
- Apr 12th, 2024 12:30 pm
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
- Apr 10th, 2024 11:00 pm
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
- Apr 9th, 2024 12:30 pm
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
- Apr 5th, 2024 1:29 pm
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
- Feb 21st, 2024 1:30 pm
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
- Feb 7th, 2024 2:27 pm
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
- Jan 30th, 2024 1:30 pm
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
- Jan 9th, 2024 1:45 pm
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
- Dec 27th, 2023 10:00 pm
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
- Dec 14th, 2023 2:24 pm
We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
- Dec 6th, 2023 12:41 pm
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
- Dec 5th, 2023 1:00 pm
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
- Dec 4th, 2023 9:01 pm
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
- Nov 28th, 2023 1:45 pm
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
- Nov 13th, 2023 2:20 pm
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
- Nov 9th, 2023 2:00 pm
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
- Nov 6th, 2023 1:30 pm
NeuroSense Therapeutics to Participate in BIO-Europe Fall
- Nov 1st, 2023 1:00 pm
Scroll